Revolutionizing Patient Comfort: Paperplane Therapeutics Secures $1.5 Million in Funding
Montreal-based Paperplane Therapeutics has successfully garnered .5 million in funding aimed at alleviating pain and anxiety for patients through innovative virtual reality (VR) therapies, potentially transforming the dental experience into a more enjoyable one.
A New Era of Healthcare Innovation
Specializing in therapeutic VR solutions, Paperplane Therapeutics focuses on effectively managing both pain and anxiety within the healthcare sector. The recent funding round was spearheaded by Glen Ventures, with contributions from Investissement Québec, an arm of the Government of Quebec. Other noteworthy strategic investors included CABHI (Centre for Aging + Brain Health Innovation), the Cedars-Sinai Intellectual Property Company, Anges Québec, and Aventure Capital.
The Challenge Posed by Pain and Anxiety
Pain and anxiety present considerable challenges that prevent patients from pursuing timely medical treatment. This issue is particularly significant in dentistry; statistically, around 36% of individuals report experiencing anxiety during dental visits while 12% are affected by severe dental phobia. Furthermore, 22% delay appointments until they can no longer avoid seeking help due to discomfort—resulting in higher costs and more complex care needs.
Pioneering Change in Dental Care Experience
Aiming to address these urgent concerns head-on, Paperplane is turning its attention to the North American dental market. Their mission centers on enhancing patient encounters as well as clinical operations through groundbreaking VR solutions designed specifically for this arena.
The integration of immersive VR technologies helps overhaul perceptions surrounding dental procedures—often regarded as daunting—to create manageable experiences or even moments of enjoyment during treatment.
Tailored Solutions for All Ages
Paperplane’s innovative offerings cater to patients across different age groups but place a particular focus on pediatric care. By prioritizing patient comfort over discomforting experiences associated with traditional treatments, their approach also optimizes workflow efficiency for healthcare providers.
A Visionary Approach to Healthcare
“As someone who has worked as an emergency physician,” stated Jean-Simon Fortin, CEO of Paperplane Therapeutics, “I have directly witnessed the limited options available for effectively addressing pain and anxiety issues.” He emphasized his pride at seeing how their VR technology can bridge that gap by equipping healthcare professionals with better tools to assist their patients efficiently—further stating that this funding will enable them to broaden their outreach considerably.
Milestone Funding Fuels Expansion Plans
This investment represents a vital turning point in Paperplane’s development journey; it paves the way for increased deployment of virtual reality therapies within dentistry while bolstering overall patient outcomes throughout North America. Additionally, it supports plans for international growth into Europe via a collaboration with French firm HypnoVR—a partnership further endorsed by CE Mark certification.
An Endorsement from Leadership Figures
Michael Goodman from Glen Ventures commented on this initiative: ”Paperplane is setting new benchmarks in how we manage pain and anxiety within healthcare settings.” He noted that besides prioritizing patient comfort levels during treatments, their methods promise enhancements related to clinical workflows—a compelling reason why they are eager supporters of such medical innovations.
Christopher Skeete—the Minister responsible for Quebec’s economic sector—echoed these sentiments: “Quebec has significant potential when it comes down to reshaping our overall healthcare landscape,” showcasing companies like Paperplane itself as exemplars driving innovation forward.”
